Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)

Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history.

Q3 2025 revenue increased between 22% and 24% vs Q3 2024 and between 12% and 14% sequentially vs the prior quarter

First nine months of 2025 revenue increased 39-40% vs first nine months of 2024.

EDEN PRAIRIE, Minn., Oct. 06, 2025 (GLOBE NEWSWIRE) --Sanuwave Health, Inc.(the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the third quarter of 2025 are expected to be in the range of $11.4 to $11.6 million, an increase of 22% to 24% over Q3 2024. This number is below the $12-$12.7 million range of guidance given in the Company’s Q2 2025 earnings release issued on August 8, 2025.

“Q3 turned out of be a more challenging quarter than we expected,” said CEO Morgan Frank. “The wound care space has had quite a lot of uncertainty around the proposed reimbursement changes for certain treatment modalities, particularly skin substitutes/grafts. This uncertainty seems to have frozen the market a bit, particularly early in the quarter. Purchase decisions were delayed and patient counts reduced as providers seemed to take a ‘wait and see’ approach to potential changes. This made for a difficult environment. All in all, I think the team did well to achieve 12-14% sequential growth during this period and 22-24% vs the ‘pig through a python’ quarter last year. Despite the headwinds, we sold a record number of systems in the quarter. That said, we fell short of our target and of our guidance (the first time this has happened in my tenure as CEO). The quarter started slowly, and we simply could not make up the ground despite ending on a high note with September being the highest revenue month in Sanuwave history. That said, based on the performance in Q3, we feel it prudent at this time to alter our 2025 annual revenue guidance from $48-$50 million to $44-$46 million.

As many have asked, UltraMIST reimbursement is not affected by the potential changes in allograft reimbursement and, while it is not yet final, based upon the guidance we have seen so far, we expect reimbursement for the 97610 code to increase very slightly in 2026 as compared to 2025. While the current disruption has been a near-term challenge, we suspect it represents a significant future opportunity, and we continue to feel good about our pipeline and our progress.”

The Company will host a conference call to discuss these numbers on October 6, 2025 at 5:30pm ET.

Telephone access to the call will be available by dialing the following numbers:

OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1738423&tp_key=183915dcd6

A replay will be made available through October 27, 2025:

Toll-Free: 1-844-512-2921 or 1-412-317-6671

Replay Access ID: 11160198

The Company plans to release its full Q3 2025 results on or around November 7, 2025.

The preliminary revenue results described herein are based on management’s initial analysis of the third quarter ended September 30, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.

Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.